U.S. flag An official website of the United States government

On Oct. 1, 2024, the FDA began implementing a reorganization impacting many parts of the agency. We are in the process of updating FDA.gov content to reflect these changes.

  1. Home
  2. Inspections, Compliance, Enforcement, and Criminal Investigations
  3. Compliance Actions and Activities
  4. Warning Letters
  5. Boehringer Ingelheim Animal Health USA - 674535 - 09/25/2024
  1. Warning Letters

CLOSEOUT LETTER

Boehringer Ingelheim Animal Health USA MARCS-CMS 674535 —

Product:
Animal & Veterinary

Recipient:
Recipient Name
Randolph Legg
Recipient Title
President and Head of Commercial Business
Boehringer Ingelheim Animal Health USA

3239 Satellite Blvd
Duluth, GA 30096
United States

Issuing Office:
Center for Veterinary Medicine

United States

Secondary Issuing Offices

United States


Dear Mr. Legg:

The Food and Drug Administration has completed evaluation of your firm’s response to our Warning Letter dated March 1, 2024. Based on our evaluation, it appears that you have addressed the violations contained in this Warning Letter.

This letter does not relieve you or your firm from the responsibility of taking all necessary steps to assure sustained compliance with the Federal Food, Drug, and Cosmetic Act and its implementing regulations or with other relevant legal authority. The Agency expects you and your firm to maintain compliance and will continue to monitor your state of compliance. This letter will not preclude any future regulatory action should violations be observed during subsequent surveillance or through other means.

If you have any questions or comments, please contact Dr. Christopher Loss at christopher.loss@fda.hhs.gov. If you wish to send a response, please direct your response to the undersigned at the Food and Drug Administration, Center for Veterinary Medicine, Office of Surveillance and Compliance, Division of Pharmacovigilance and Surveillance, 12225 Wilkins Ave, MPN II Room E474, Rockville, Maryland 20852. Please send a courtesy copy by email to CVMSurveillance@fda.hhs.gov. All correspondence should include a subject line that clearly identifies the submission as a Response to Warning Letter # 674535.


Sincerely,
/S/
Linda Walter-Grimm, DVM
Director, Division of Pharmacovigilance and Surveillance
Office of Surveillance and Compliance
Center for Veterinary Medicine

Back to Top